<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Ifosfamide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01181</strong>&#160; (APRD00007)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppresive agent.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01181/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01181/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01181.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01181.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01181.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01181.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01181.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01181">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Iphosphamide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Isofosfamide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Isophosphamide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Isosfamide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Celofos</td><td>Celon</td></tr><tr><td>Cuantil</td><td>Teva</td></tr><tr><td>Holoxan</td><td>Baxter</td></tr><tr><td>Ifex</td><td>Baxter</td></tr><tr><td>Mitoxana</td><td>Baxter</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>3778-73-2</td></tr><tr><th>Weight</th><td>Average: 261.086<br>Monoisotopic: 260.02481966</td></tr><tr><th>Chemical Formula</th><td>C<sub>7</sub>H<sub>15</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub>P</td></tr><tr><th>InChI Key</th><td>HOMGKSMUEGBAAB-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">3-(2-chloroethyl)-2-[(2-chloroethyl)amino]-1,3,2$l^{5}-oxazaphosphinan-2-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">ClCCNP1(=O)OCCCN1CCCl</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Oxazaphosphinanes</td></tr><tr><th>Subclass</th><td>Isofamides</td></tr><tr><th>Direct parent</th><td>Isofamides</td></tr><tr><th>Alternative parents</th><td>Phosphorodiamides; Organophosphate Esters; Polyamines; Organochlorides; Alkyl Chlorides</td></tr><tr><th>Substituents</th><td>phosphorodiamide; phosphoric acid ester; polyamine; organochloride; organonitrogen compound; amine; organohalogen; alkyl halide; alkyl chloride</td></tr><tr><th>Classification description</th><td>This compound belongs to the isofamides. These are oxazaphospholanes containing the isofamide skeleton. isofamide is an heterocyclic compound made up of a 1,3,2-oxazaphospholane, where the phosphorus atom is part of a phosphodiamide group, and the oxazaphospholane is substituted by two haloalkyl chains.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.</td></tr><tr><th>Pharmacodynamics</th><td>Ifosfamide requires activation by microsomal liver enzymes to active metabolites in order to exert its cytotoxic effects. Activation occurs by hydroxylation at the ring carbon atom 4 to form the unstable intermediate 4-hydroxyifosfamide. This metabolite than rapidly degrades to the stable urinary metabolite 4-ketoifosfamide. The stable urinary metabolite, 4-carboxyifosfamide, is formed upon opening of the ring. These urinary metabolites have not been found to be cytotoxic. N, N-bis (2-chloroethyl)-phosphoric acid diamide (ifosphoramide) and acrolein are also found. The major urinary metabolites, dechloroethyl ifosfamide and dechloroethyl cyclophosphamide, are formed upon enzymatic oxidation of the chloroethyl side chains and subsequent dealkylation. It is the alkylated metabolites of ifosfamide that have been shown to interact with DNA. Ifosfamide is cycle-phase nonspecific.</td></tr><tr><th>Mechanism of action</th><td>The exact mechanism of ifosfamide has not been determined, but appears to be similar to other alkylating agents. Ifosfamide requires biotransformation in the liver by mixed-function  oxidases (cytochrome P450 system) before it becomes active. After metabolic activation, active metabolites of ifosfamide alkylate or bind with many intracellular molecular structures, including nucleic acids. The cytotoxic action is primarily through the alkylation of DNA, done by attaching the N-7 position of guanine to its reactive electrophilic groups. The formation of inter and intra strand cross-links in the DNA results in cell death.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><p>Ifosfamide volume of distribution (Vd) approximates the total body water volume, suggesting that distribution takes place with minimal tissue binding. Following intravenous administration of 1.5 g/m2 over 0.5 hour once daily for 5 days to 15 patients with neoplastic disease, the median Vd of ifosfamide was 0.64 L/kg on Day 1 and 0.72 L/kg on Day 5. When given to pediatric patients, the volume of distribution was  21&#177;1.6 L/m^2.</p></td></tr><tr><th>Protein binding</th><td>Ifosfamide shows little plasma protein binding. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Primarily hepatic. Ifosfamide is metabolized through two metabolic pathways: ring oxidation ("activation") to form the active metabolite, 4-hydroxy-ifosfamide and side-chain oxidation to form the inactive metabolites, 3-dechloro-ethylifosfamide or 2-dechloroethylifosfamide with liberation of the toxic metabolite, chloroacetaldehyde.  Small quantities (nmol/mL) of ifosfamide mustard and 4-hydroxyifosfamide are detectable in human plasma. Metabolism of ifosfamide is required for the generation of the biologically active species and while metabolism is extensive, it is also quite variable among patients.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Ifosfamide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0003549" target="_blank">Cytochrome P450 2B6</a></li>
<li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li></ul></td><td><a href="/metabolites/DBMET00021">3-Dechloroethylifosfamide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/21">Details</a></td></tr><tr><td>Ifosfamide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0003549" target="_blank">Cytochrome P450 2B6</a></li>
<li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li></ul></td><td><a href="/metabolites/DBMET00022">2-Dechloroethylifosfamide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/22">Details</a></td></tr><tr><td>Ifosfamide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0003549" target="_blank">Cytochrome P450 2B6</a></li></ul></td><td><a href="/metabolites/DBMET00023">Chloroacetaldehyde</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/23">Details</a></td></tr><tr><td>Ifosfamide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0000017" target="_blank">Prostaglandin G/H synthase 1</a></li>
<li><a href="/biodb/bio_entities/BE0003549" target="_blank">Cytochrome P450 2B6</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0003336" target="_blank">Cytochrome P450 2A6</a></li>
<li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li></ul></td><td><a href="/metabolites/DBMET00024">4-Hydroxyifosfamide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/24">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00024">4-Hydroxyifosfamide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01077">4-Ketoifosfamide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1063">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00024">4-Hydroxyifosfamide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00792">aldoifosfamide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1064">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00024">4-Hydroxyifosfamide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01100">4-Thioifosfamide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1182">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00792">aldoifosfamide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01102">Alcoifosfamide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1187">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00792">aldoifosfamide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0000554" target="_blank">Retinal dehydrogenase 1</a></li></ul></td><td><a href="/metabolites/DBMET01103">Carboxylifosfamide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1188">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00792">aldoifosfamide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01126">Acrolein</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1235">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00792">aldoifosfamide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01127">Isophosphamide mustard</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1236">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01126">Acrolein</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0000554" target="_blank">Retinal dehydrogenase 1</a></li>
<li><a href="/biodb/bio_entities/BE0000718" target="_blank">Aldehyde dehydrogenase, dimeric NADP-preferring</a></li></ul></td><td><a href="/metabolites/DBMET01146">Acrylic Acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1280">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01127">Isophosphamide mustard</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01150">Ifosforamide Aziridinium</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1281">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Ifosfamide is extensively metabolized in humans and the metabolic pathways appear to be saturated at high doses. After administration of doses of 5 g/m2 of 14C-labeled ifosfamide, from 70% to 86% of the dosed radioactivity was recovered in the urine, with about 61% of the dose excreted as parent compound.  At doses of 1.6&#8211;2.4 g/m2 only 12% to 18% of the dose was excreted in the urine as unchanged drug within 72 hours.</td></tr><tr><th>Half life</th><td>7-15 hours. The elimination half-life increase appeared to be related to the increase in ifosfamide volume of distribution with age.</td></tr><tr><th>Clearance</th><td><ul>
	<li>2.4&#177;0.33 L/h/m^2 [pediatric patients]</li>
</ul></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub> (mouse) = 390-1005 mg/kg, LD<sub>50</sub> (rat) = 150-190 mg/kg. Side effects include nausea, vomiting and myelosuppression. Toxic effects include central nervous system toxicity (confusion, hallucinations) and urotoxic effects (cystitis, blood in urine).</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th><th>SMPDB ID</th></tr></thead><tbody><tr><td>Ifosfamide Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00448?highlight%5Bcompounds%5D%5B%5D=DB01181&amp;highlight%5Bproteins%5D%5B%5D=DB01181">SMP00448</a></td></tr><tr><td>Ifosfamide Metabolism Pathway</td><td>Drug metabolism</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00605?highlight%5Bcompounds%5D%5B%5D=DB01181&amp;highlight%5Bproteins%5D%5B%5D=DB01181">SMP00605</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9807</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9736</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5411</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7098</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6204</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9617</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8135</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7674</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5922</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8835</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9723</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.9108
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8903
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.7807
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.2294 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Strong inhibitor 
        </td>
        <td>
            0.8985
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8224
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Baxter healthcare corp</li>
<li>App pharmaceuticals llc</li>
<li>Teva parenteral medicines inc</li>
<li>Bedford laboratories div ben venue laboratories inc</li>
<li>Sagent strides llc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.bms.com">Bristol-Myers Squibb Co.</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, powder, for solution</td><td>Intravenous</td><td>1 g, 3 g</td></tr><tr><td>Kit</td><td>Intravenous</td><td>1-1 GM </td></tr><tr><td>Solution</td><td>Intravenous</td><td>1 g/20 mL; 3 g/60 mL  </td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Ifex-mesnex kit</td><td>2709.98USD</td><td>kit</td></tr><tr><td>Ifosfamide-mesna kit</td><td>787.5USD</td><td>kit</td></tr><tr><td>Ifex 3 gm vial</td><td>489.13USD</td><td>vial</td></tr><tr><td>Ifex 1 gm vial</td><td>163.04USD</td><td>vial</td></tr><tr><td>Ifosfamide 3 gm vial</td><td>114.0USD</td><td>vial</td></tr><tr><td>Ifosfamide 1 gm vial</td><td>56.4USD</td><td>vial</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>5252341</td><td>1994-07-16</td><td>2011-07-16</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>39-41 &#176;C</td><td>U.S. Patent 3,732,340.</td></tr><tr><td>water solubility</td><td>3780 mg/L</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>logP</td><td>0.86</td><td>HANSCH,C ET AL. (1995)</td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>1.50e+01 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>0.57</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>0.097</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-1.2</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>13.24</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>0.12</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>41.57</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>58.48</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>23.94</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>U.S. Patent 3,732,340.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=3732340&amp;tbm=pts" target="_blank">US3732340 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Furlanut M, Franceschi L: Pharmacology of ifosfamide. Oncology. 2003;65 Suppl 2:2-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14586139">Pubmed</a></li>
	<li>Fleming RA: An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy. 1997 Sep-Oct;17(5 Pt 2):146S-154S. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9322882">Pubmed</a></li>
	<li>Wagner T: Ifosfamide clinical pharmacokinetics. Clin Pharmacokinet. 1994 Jun;26(6):439-56. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8070218">Pubmed</a></li>
	<li>Allen LM, Creaven PJ, Nelson RL: Studies on the human pharmacokinetics of isophosphamide (<span class="caps">NSC</span>-109724). Cancer Treat Rep. 1976 Apr;60(4):451-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1277221">Pubmed</a></li>
	<li>Brade WP, Herdrich K, Varini M: Ifosfamide&#8212;pharmacology, safety and therapeutic potential. Cancer Treat Rev. 1985 Mar;12(1):1-47. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3896483">Pubmed</a></li>
	<li>Zalupski M, Baker LH: Ifosfamide. J Natl Cancer Inst. 1988 Jun 15;80(8):556-66. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3286879">Pubmed</a></li>
	<li>Willits I, Price L, Parry A, Tilby MJ, Ford D, Cholerton S, Pearson AD, Boddy AV: Pharmacokinetics and metabolism of ifosfamide in relation to <span class="caps">DNA</span> damage assessed by the <span class="caps">COMET</span> assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15827549">Pubmed</a></li>
	<li>Lokiec F: Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention. Ann Oncol. 2006 May;17 Suppl 4:iv33-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16702183">Pubmed</a></li>
	<li>Schoenike SE, Dana WJ: Ifosfamide and mesna. Clin Pharm. 1990 Mar;9(3):179-91. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2107997">Pubmed</a></li>
	<li>Dechant KL, Brogden RN, Pilkington T, Faulds D: Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs. 1991 Sep;42(3):428-67. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1720382">Pubmed</a></li>
	<li><span class="caps">FDA</span> label</li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D00343" target="_blank">D00343 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C07047" target="_blank">C07047 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3690" target="_blank">3690 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46508335" target="_blank">46508335 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.3562.html" target="_blank">3562 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=5864" target="_blank">5864 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1024" target="_blank">CHEMBL1024 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000537" target="_blank">DAP000537 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA449964" target="_blank">PA449964 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2246565" target="_blank">2246565 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic2/ifosfamide.htm" target="_blank">http://www.rxlist.com/cgi/generic2/ifosfamide.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/ifosfamide-solution.html" target="_blank">http://www.drugs.com/cdi/ifosfamide-solution.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Ifosfamide" target="_blank">Ifosfamide <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>L01AA06<ul class="atc-drug-tree"><li><a href="/atc/L#L">L &#8212; ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</a></li><li><a href="/atc/L01#L01">L01 &#8212; ANTINEOPLASTIC AGENTS</a></li><li><a href="/atc/L01A#L01A">L01A &#8212; ALKYLATING AGENTS</a></li><li><a href="/atc/L01AA#L01AA">L01AA &#8212; Nitrogen mustard analogues</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>10:00.00</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB01181.pdf?1265922738">show</a>(293 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00673">Aprepitant</a></td><td>Aprepitant may change levels of the chemotherapy agent, ifosfamide.</td></tr><tr><td><a href="/drugs/DB06769">Bendamustine</a></td><td>Increases toxicity through pharmacodynamic synergism. Additive myelosuppression.</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Ifosfamide, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience an increase in the serum concentrations of its active metabolites. It is recommended to monitor for toxicity of ifosfamide therapy.</td></tr><tr><td><a href="/drugs/DB06589">Pazopanib</a></td><td>Ifosfamide decreases plasma levels of pazopanib. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Ifosfamide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ifosfamide if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00208">Ticlopidine</a></td><td>Ticlopidine may decrease the metabolism and clearance of Ifosfamide. Consider alternate therapy or monitor for adverse/toxic effects of Ifosfamide if Ticlopidine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Tranylcypromine, a strong CYP2A6 inhibitor, may decrease the metabolism and clearance of Ifosmadine. </td></tr><tr><td><a href="/drugs/DB00072">Trastuzumab</a></td><td>Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ifosfamide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ifosfamide if voriconazole is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>